Browsing Tag

1a1b

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver…

Jason Junior Oct 13, 2021

MENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced…

Health

NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in…

Jason Junior Sep 16, 2021

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1a/1b study with no dose-limiting toxicitiesAll six…

Health

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for…

Jason Junior Aug 11, 2021

CB4211 was well-tolerated and appeared safe with no serious adverse eventsRobust reductions in ALT and AST Reduction in glucose and trend towards body weight reductionCompany to host conference call and webcast at 5:00 p.m. ET MENLO PARK,…

Health

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and…

Jason Junior Jul 15, 2021

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced…